局部晚期直肠癌免疫检查点抑制后的器官保存。

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical colorectal cancer Pub Date : 2024-12-15 DOI:10.1016/j.clcc.2024.12.005

Charlotte Claeys , Antoon Billiet , Karin Haustermans , Albert Wolthuis , Gabriele Bislenghi , André D'Hoore , Raphaëla Dresen , Gertjan Rasschaert , Eric Van Cutsem , Filip Van Herpe , Jeroen Dekervel

{"title":"局部晚期直肠癌免疫检查点抑制后的器官保存。","authors":"Charlotte Claeys , Antoon Billiet , Karin Haustermans , Albert Wolthuis , Gabriele Bislenghi , André D'Hoore , Raphaëla Dresen , Gertjan Rasschaert , Eric Van Cutsem , Filip Van Herpe , Jeroen Dekervel","doi":"10.1016/j.clcc.2024.12.005","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Immune checkpoint inhibition (ICI) targeting PD-1 (programmed cell death protein 1) is the standard treatment for metastatic microsatellite instable (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer, producing long-lasting responses. Emerging evidence suggests an important role for neoadjuvant ICI in local and locoregional disease, especially in anatomical regions associated with high surgical morbidity.</div></span></li><li><span>•</span><span><div>We report single-center data of the clinical course and outcome of 6 eligible patients with dMMR locally advanced rectal cancer (LARC) treated with off-label ICI as part of their initial treatment.</div></span></li><li><span>•</span><span><div>Meaningful clinical responses were noted in all evaluable patients. Four patients had a complete clinical response, followed by active surveillance. Two patients had a partial response and underwent surgery. After a median follow-up of 25.8 months, no local or distant recurrences were noted.</div></span></li><li><span>•</span><span><div>The role of immunotherapy in dMMR LARC is promising, although more prospective clinical trials with a longer follow-up are required.</div></span></li></ul></div></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"24 2","pages":"Pages 320-324"},"PeriodicalIF":3.3000,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Organ Preservation After Immune Checkpoint Inhibition for Locally Advanced Rectal Cancer\",\"authors\":\"Charlotte Claeys , Antoon Billiet , Karin Haustermans , Albert Wolthuis , Gabriele Bislenghi , André D'Hoore , Raphaëla Dresen , Gertjan Rasschaert , Eric Van Cutsem , Filip Van Herpe , Jeroen Dekervel\",\"doi\":\"10.1016/j.clcc.2024.12.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><ul><li><span>•</span><span><div>Immune checkpoint inhibition (ICI) targeting PD-1 (programmed cell death protein 1) is the standard treatment for metastatic microsatellite instable (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer, producing long-lasting responses. Emerging evidence suggests an important role for neoadjuvant ICI in local and locoregional disease, especially in anatomical regions associated with high surgical morbidity.</div></span></li><li><span>•</span><span><div>We report single-center data of the clinical course and outcome of 6 eligible patients with dMMR locally advanced rectal cancer (LARC) treated with off-label ICI as part of their initial treatment.</div></span></li><li><span>•</span><span><div>Meaningful clinical responses were noted in all evaluable patients. Four patients had a complete clinical response, followed by active surveillance. Two patients had a partial response and underwent surgery. After a median follow-up of 25.8 months, no local or distant recurrences were noted.</div></span></li><li><span>•</span><span><div>The role of immunotherapy in dMMR LARC is promising, although more prospective clinical trials with a longer follow-up are required.</div></span></li></ul></div></div>\",\"PeriodicalId\":10373,\"journal\":{\"name\":\"Clinical colorectal cancer\",\"volume\":\"24 2\",\"pages\":\"Pages 320-324\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical colorectal cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S153300282400118X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical colorectal cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S153300282400118X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

•针对PD-1（程序性细胞死亡蛋白1）的免疫检查点抑制（ICI）是转移性微卫星不稳定(MSI-H)/错配修复缺陷（dMMR）结直肠癌的标准治疗方法，可产生持久的应答。越来越多的证据表明，新辅助ICI在局部和局部疾病中发挥重要作用，特别是在与高手术发病率相关的解剖区域。•我们报告了6例符合条件的dMMR局部晚期直肠癌（LARC）患者的临床过程和结果的单中心数据，这些患者接受了说明书外ICI治疗，作为初始治疗的一部分。•在所有可评估的患者中都注意到有意义的临床反应。4例患者有完全的临床反应，随后进行了主动监测。两名患者有部分反应并接受了手术。中位随访25.8个月后，未发现局部或远处复发。•免疫治疗在dMMR LARC中的作用是有希望的，尽管需要更多的前瞻性临床试验和更长的随访时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Organ Preservation After Immune Checkpoint Inhibition for Locally Advanced Rectal Cancer

•
Immune checkpoint inhibition (ICI) targeting PD-1 (programmed cell death protein 1) is the standard treatment for metastatic microsatellite instable (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer, producing long-lasting responses. Emerging evidence suggests an important role for neoadjuvant ICI in local and locoregional disease, especially in anatomical regions associated with high surgical morbidity.
•
We report single-center data of the clinical course and outcome of 6 eligible patients with dMMR locally advanced rectal cancer (LARC) treated with off-label ICI as part of their initial treatment.
•
Meaningful clinical responses were noted in all evaluable patients. Four patients had a complete clinical response, followed by active surveillance. Two patients had a partial response and underwent surgery. After a median follow-up of 25.8 months, no local or distant recurrences were noted.
•
The role of immunotherapy in dMMR LARC is promising, although more prospective clinical trials with a longer follow-up are required.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical colorectal cancer 医学-肿瘤学

CiteScore

5.50

自引率

2.90%

发文量

审稿时长

27 days

期刊介绍： Clinical Colorectal Cancer is a peer-reviewed, quarterly journal that publishes original articles describing various aspects of clinical and translational research of gastrointestinal cancers. Clinical Colorectal Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of colorectal, pancreatic, liver, and other gastrointestinal cancers. The main emphasis is on recent scientific developments in all areas related to gastrointestinal cancers. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.